Joint position statement of the diagnosis and management of light chain amyloidosis and light chain cardiac amyloidosis by the Taiwan Society of Cardiology (TSOC) and the Hematology Society of Taiwan (HST).
{"title":"Joint position statement of the diagnosis and management of light chain amyloidosis and light chain cardiac amyloidosis by the Taiwan Society of Cardiology (TSOC) and the Hematology Society of Taiwan (HST).","authors":"Yen-Wen Wu, Chao-Hung Wei, Yen-Hung Lin, Shang-Yi Huang, Yen-Wen Liu, Tran-Der Tan, Wen-Chung Yu, Chia-Jen Liu, Chung-Lieh Hung, Po-Shen Ko, Ning-I Yang, Shih-Feng Cho, Chun-Yao Huang, Chun-Kai Liao, Chieh-Lin Jerry Teng, Tsai-Yun Chen, Wen-Jone Chen, Bor-Sheng Ko","doi":"10.1016/j.jfma.2025.05.006","DOIUrl":null,"url":null,"abstract":"<p><p>Light chain (AL) amyloidosis, defined by the organ deposition of misfolded and aggregated amyloid light chain, is the most common subtype of systematic amyloidosis with an incidence rate of around 1 case per 100,000 person-years in Taiwan. Due to its rarity, and heterogeneous initial presentation depending on the affected organs, diagnosis and management of AL amyloidosis are challenging. To increase the awareness of AL amyloidosis across clinical specialties and provide evidence-based recommendations, the Taiwan Society of Cardiology (TSOC) and Hematology Society of Taiwan (HST) have jointly developed a position statement. The joint statement provides diagnosis and management recommendations for systematic AL amyloidosis and AL cardiac amyloidosis under Taiwan's medical context.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Formosan Medical Association","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jfma.2025.05.006","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Light chain (AL) amyloidosis, defined by the organ deposition of misfolded and aggregated amyloid light chain, is the most common subtype of systematic amyloidosis with an incidence rate of around 1 case per 100,000 person-years in Taiwan. Due to its rarity, and heterogeneous initial presentation depending on the affected organs, diagnosis and management of AL amyloidosis are challenging. To increase the awareness of AL amyloidosis across clinical specialties and provide evidence-based recommendations, the Taiwan Society of Cardiology (TSOC) and Hematology Society of Taiwan (HST) have jointly developed a position statement. The joint statement provides diagnosis and management recommendations for systematic AL amyloidosis and AL cardiac amyloidosis under Taiwan's medical context.
期刊介绍：
Journal of the Formosan Medical Association (JFMA), published continuously since 1902, is an open access international general medical journal of the Formosan Medical Association based in Taipei, Taiwan. It is indexed in Current Contents/ Clinical Medicine, Medline, ciSearch, CAB Abstracts, Embase, SIIC Data Bases, Research Alert, BIOSIS, Biological Abstracts, Scopus and ScienceDirect.
As a general medical journal, research related to clinical practice and research in all fields of medicine and related disciplines are considered for publication. Article types considered include perspectives, reviews, original papers, case reports, brief communications, correspondence and letters to the editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
